Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 3 Δεκ 2018 · When an episode of care involves the surgical removal of a neoplasm, primary or secondary site, followed by adjunct chemotherapy or radiation treatment during the same episode of care, the code for the neoplasm should be assigned as principal or first-listed diagnosis.

  2. 18 Μαΐ 2020 · A particularly debilitating consequence of MKIs is hand-foot skin reaction (HFSR), which manifests as symmetric hyperkeratotic plaques with serious inflammation over sites of pressure or friction .

  3. 18 Οκτ 2022 · When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug (T36-T50).

  4. 27 Νοε 2017 · An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. An AE is a term that is a unique

  5. www.ons.org › Oct_2020_CJON_clinicalsummarytreatmentrelatedskintoxicitySkin Toxicity - ONS

    Cancer treatment–related skin toxicities are a frequent and distressing side efect of antineo-plastic therapies, especially chemotherapy and targeted therapies. Skin toxicities associated with these therapies can include rashes, hand-foot skin reaction, hand-foot syndrome, and hair loss.

  6. Results: The panel issued seven conditional recommendations for epidermal growth factor receptor inhibitor rash, hand-foot skin reaction, hand-foot syndrome, and chemotherapy-induced alopecia. The panel suggested strategies for prevention and treatment for all toxicities except hand-foot syndrome, which only has a prevention recommendation.

  7. 1 Σεπ 2020 · Background: Management of cancer treatment-related skin toxicities can minimize treatment disruptions and improve patient well-being. Objectives: This guideline aims to support patients and clinicians in decisions regarding management of cancer treatment-related skin toxicities.